| Literature DB >> 28622372 |
Wei-Cheng Chang1, Chin Lin2,3, Cho-Hao Lee4, Tzu-Ling Sung2, Tao-Hsin Tung5,6, Jorn-Hon Liu1.
Abstract
BACKGROUND: Studies on vitrectomy with and without internal limiting membrane (ILM) peeling for idiopathic epiretinal membrane (ERM) have yielded uncertain results regarding clinical outcomes and recurrence rates.Entities:
Mesh:
Year: 2017 PMID: 28622372 PMCID: PMC5473547 DOI: 10.1371/journal.pone.0179105
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of the process of identifying eligible studies.
Summary of studies included in the meta-analysis.
| Study | Country | Study type | Quality score | Group | No. of eyes | Mean age (yr) | Follow-up duration (mo) | Preoperative BCVA (LogMAR) | Preoperative CRT (um) | |
|---|---|---|---|---|---|---|---|---|---|---|
| >12 | >6 | |||||||||
| Kim et al., 2005 | Korea | Retro | 6 | 7 | Non-ILM peeling | 17 | 61.6 | 11.2 | 0.71+-0.50 | 418+-71 |
| ILM peeling | 17 | 63.5 | 8.9 | 0.71+-0.16 | 483+-261 | |||||
| Kwok et al., 2005 | Hong Kong | Retro | 8 | 8 | Non-ILM peeling | 15 | 69.1+-8.3 | 47.9+-18.1 | 0.96+-0.18 | - |
| ILM peeling | 20 | 63.8+-9.3 | 23.9+-5.5 | 0.77+-0.50 | - | |||||
| Liu et al., 2005 | Japan | Retro | 7 | 7 | Non-ILM peeling | 20 | 68.2+-6.9 | 3 | 0.44+-0.21 | 402.7+-110.3 |
| ILM peeling | 18 | 69.4+-5.7 | 3 | 0.35+-0.26 | 385.6+-117.2 | |||||
| Mason et al., 2006 | American | Retro | 8 | 8 | Non-ILM peeling | 20 | 70(33–84) | 16 | - | - |
| ILM peeling | 20 | 68(53–78) | 16 | - | - | |||||
| Lee et al., 2010 | Korea | Retro | 8 | 8 | Non-ILM peeling | 19 | 65.47+-7.66 | 18.2+-12.0 | 0.67+-0.34 | 398.42+-95.43 |
| ILM peeling | 21 | 63.43+-7.18 | 18.05+-11.81 | 0.68+-0.21 | 409.43+-111.62 | |||||
| Pournaras et al., 2011 | Switzerland | Retro | 7 | 8 | Non-ILM peeling | 15 | 77.1+-6.7 | 41.9+-35.6 | 0.48+-0.22 | - |
| ILM peeling | 24 | 73.3+-10.6 | 24.0+-12.6 | 0.58+-0.40 | 401+-96 | |||||
| Chuang et al., 2012 | Taiwan | Retro | 8 | 8 | Non-ILM peeling | 61 | 62.08+-10.52 | 21.97+-11.08 | 0.14+-0.11 | 462.70+-83.90 |
| ILM peeling | 20 (TA) | 63.80+-9.63 | 17.55+-4.19 | 0.21+-0.18 | 470.30+-87.34 | |||||
| Oh et al., 2013 | Korea | Retro | 7 | 8 | Non-ILM peeling | 23 | 64 | 12 | 0.35+-0.16 | - |
| ILM peeling | 20 | 65.3 | 12 | 0.44+-0.21 | - | |||||
| Ahn et al., 2014 | Korea | Retro | 7 | 8 | Non-ILM peeling | 69 | 63.9+-11.1 | 12 | 0.38+-0.19 | 456+-77.4 |
| ILM peeling | 40 | 64.3+-10.0 | 12 | 0.31+-0.21 | 445+-99.3 | |||||
| Reilly et al., 2015 | American | Retro | 6 | 7 | Non-ILM peeling | 78 | - | - | 0.324(phakic) | - |
| ILM peeling | 51 | - | - | 0.292(phakic) | - | |||||
| Jung et al., 2016 | American | Retro | 8 | 8 | Non-ILM peeling | 43 | 68.6 | 36.3 | 0.53 | - |
| ILM peeling | 42 | 71.5 | 29.9 | 0.52 | - | |||||
| Ripandell et al., 2015 | Italy | RCT | Non-ILM peeling | 30 | - | 12 | 0.298+-0.1082 | 473.80+-75.70 | ||
| ILM peeling | 30 | - | 12 | 0.306+-0.214 | 464.20+-89.20 | |||||
Retro: retrospective study; Quality score: assessed the quality of retrospective studies according to the Newcastle–Ottawa Scale (NOS), we formed two groups by using different scoring methods assuming that the follow-up time was sufficiently long, 6 months or 12 months; yr: year; mo: month
Summary of studies included in the meta-analysis.
| Study | Group | Postoperative BCVA (LogMAR) | VA improvement | Postoperative CRT(um) | CRT decrease (um) | ERM recurrence |
|---|---|---|---|---|---|---|
| Kim et al., 2005 | Non-ILM peeling | 0.37+-0.22 | 9/17 (>2lines) | 282+-72 | 197+-152 | 0% (0/17) |
| ILM peeling | 0.54+-0.22 | 8/17 (>2lines) | 328+-55 | 125+-138 | 0% (0/17) | |
| Kwok et al., 2005 | Non-ILM peeling | 0.65+-0.32 | 12/15 (>2lines) | - | - | 20% (3/15) |
| ILM peeling | 0.46+-0.37 | 11/20 (>2lines) | - | - | 10% (2/20) | |
| Liu et al., 2005 | Non-ILM peeling | 0.19+-0.17 | 12/20 (>2lines) | 295.2+-81.6 | - | - |
| ILM peeling | 0.20+-0.19 | 8/18 (>2lines) | 307.2+-60.8 | - | - | |
| Mason et al., 2006 | Non-ILM peeling | - | 100% (no mention) | - | - | 20% (4/20) |
| ILM peeling | - | 70% (no mention) | - | - | 0% (0/19) | |
| Lee et al., 2010 | Non-ILM peeling | 0.32+-0.23 | - | 282.53+-95.71 | 115.89+-107.48 | 0% (0/19) |
| ILM peeling | 0.20+-0.17 | - | 335.24+-76.91 | 74.19+-79.33 | 0% (0/21) | |
| Pournaras et al., 2011 | Non-ILM peeling | 0.37+-0.42 | 8/15 (no mention) | 268+-98 | - | - |
| ILM peeling | 0.32+-0.39 | 19/24 (no mention) | 307+-49 | - | - | |
| Chuang et al., 2012 | Non-ILM peeling | 0.41+-0.55 | - | 299.44+-63.57 | - | 13% (8/61) |
| ILM peeling | 0.39+-0.57 | - | 295.35+-86.82 | - | 0% (0/43) | |
| Oh et al., 2013 | Non-ILM peeling | 0.40+-0.18(3m) | - | - | - | |
| ILM peeling | 0.56+-0.26(3m) | - | - | - | ||
| Ahn et al., 2014 | Non-ILM peeling | 0.11+-0.12 | - | 356+-58.9 | - | 20.3% (14/69) |
| ILM peeling | 0.17+-0.17 | - | 342+-38.9 | - | 7.5% (3/40) | |
| Reilly et al., 2015 | Non-ILM peeling | 0.226(12m) | - | - | - | 5.1% (4/78) |
| ILM peeling | 0.113(12m) | - | - | - | 3.9% (2/51) | |
| Jung et al., 2016 | Non-ILM peeling | 0.41(3m) | - | - | 95.7 | 13% (5/39) |
| ILM peeling | 0.38(3m) | - | - | 67.4 | 0% (0/42) | |
| Ripandell et al., 2015 | Non-ILM peeling | 0.034+-0.1082 | - | 351.03+-40.24 | - | 0% (0/30) |
| ILM peeling | 0.048+-0.0822 | - | 376.9+-45.12 | - | 0% (0/30) |
BCVA: best-corrected visual acuity; CRT: central retinal thickness
Surgery-related features of studies included in the meta-analysis.
| Study | Group | Complication | Stain | Vitrectomy | Phakia/IOL | |
|---|---|---|---|---|---|---|
| Pre op | Post op | |||||
| Kim et al., 2005 | Non-ILM peeling | No mention | - | 15/2 | - | |
| ILM peeling | ICG | 12/5 | - | |||
| Kwok et al., 2005 | Non-ILM peeling | 1 post op RD | - | 14/1 | - | |
| ILM peeling | 1 post op RD | ICG | 17/3 | - | ||
| Liu et al., 2005 | Non-ILM peeling | No mention | - | - | 1/19 | |
| ILM peeling | - | - | 0/18 | |||
| Mason et al., 2006 | Non-ILM peeling | 10% vitrous hemorrhage, no infection, no RD, no phototoxic, no RPE damage | 25G forceps | - | - | |
| ILM peeling | ICG | - | - | |||
| Lee et al., 2010 | Non-ILM peeling | No significant complication observed | - | 18/1 | 2/17 | |
| ILM peeling | ICG | 19/2 | 1/20 | |||
| Pournaras et al., 2011 | Non-ILM peeling | No significant intraoperative or postoperative complications observed | 20G | 0/15 | 0/15 | |
| ILM peeling | ICG | 0/24 | 0/24 | |||
| Chuang et al., 2012 | Non-ILM peeling | No mention | - | - | - | |
| ILM peeling | TA/ICG | - | - | |||
| Oh et al., 2013 | Non-ILM peeling | 5 cataract(21.7%), 14 punctate retinal hemorrhage(60.9%) | 20G | 18/5 | 17/6 | |
| ILM peeling | ICG | - | 16/4 | 16/4 | ||
| Ahn et al., 2014 | Non-ILM peeling | No mention | 23G | 99/10 | 33/36 | |
| ILM peeling | 6 cataract(30.0%), 13 punctate retinal hemorrhage(65.0%) | ICG | 12/28 | |||
| Reilly et al, 2015 | Non-ILM peeling | 1 RD with PVR at post op 5 weeks, 1 choroidal neovascular membrane, 1 retinal tear s/p laser retinopexy | - | 66/63 | 32/46 | |
| ILM peeling | - | 20/31 | ||||
| Jung et al., 2016 | Non-ILM peeling | No mention | 23G | - | - | |
| ILM peeling | BBG | - | - | |||
| Ripandell et al., 2015 | Non-ILM peeling | No adverse events | 23G | 0/30 | 0/30 | |
| ILM peeling | BBG | 0/30 | 0/30 | |||
IOL: intraocular lens; Preop: preoperation; Postop: postoperation; RD: retinal detachment; RPE: retinal pigment epithelium; PVR: proliferative vitreoretinopathy; ICG: indocyanine green; TA: triamcinolone acetonide; BBG: Brilliant Blue G
Fig 2Main results from the meta-analysis of vitrectomy with epiretinal membrane (ERM) and ILM peeling or with only ERM peeling in idiopathic ERM.
(A) Best-corrected visual acuity (BCVA) <12 months follow-up duration after surgery; vitrectomy with only ERM peeling yielded significantly better results; (B) BCVA >18 months follow-up duration after surgery; vitrectomy with ERM+ILM peeling yielded significantly better results; (C) rate of improvement in visual acuity, defined as ≥2 Snellen lines at the end of follow-up; the difference between the two groups was nonsignificant (D) ERM recurrence rate; was significantly lower in the ERM + ILM peeling group than in the ERM peeling only group (E) central retinal thickness (CRT) at the end of follow-up; the difference between the two groups was nonsignificant; (F) CRT reduction at the end of follow-up; CRT reduction was significantly higher in the ERM peeling group than in the ERM+ ILM peeling group.
Summary of results.
| BCVA outcome < 12months follow up | 0.01(-0.03–0.06) | 0.5725 | 0.06(0.01–0.11) | 0.0122 | 0% | 0.04(0.00–0.08) | 0.0460 | 15.7% | 0.408 |
| BCVA outcome > 18 months follow up | - | -0.13(-0.23–0.04) | 0.0049 | 0% | - | - | - | 0.943 | |
| CRT outcome, the end of follow up | 25.87(4.24–47.50) | 0.0191 | 17.04(-7.39–41.48) | 0.1717 | 59.1% | 18.15(-2.29–38.60) | 0.0818 | 60% | 0.109 |
| CRT reduction amount | - | -51.55(-84.23–18.88) | 0.0020 | 0% | - | - | - | 0.661 | |
| VA improvement rate | - | - | 1.03(0.72–1.47) | 0.8802 | 62.8% | - | - | - | 0.239 |
| ERM recurrence rate | - | - | 0.34(0.16–0.72) | 0.0048 | 0% | 0.34(0.16–0.72) | 0.0048 | 0% | 0.083 |
P values: all represent the random effects model result
I2: index for assessing heterogeneity; value >50% indicates a moderate to high heterogeneity
Egger’s test: P value of Egger’s regression for asymmetry assessment
a: The randomized controlled trial (RCT) did not provide data of BCVA outcomes >18 months follow-up, VA improvement rate, and CRT reduction amount; hence, combining the RCT with the analysis of retrospective studies in these three outcomes was not applicable.
b: The RCT revealed no ERM recurrence in total 60 cases.
Meta-regression analysis of heterogeneity and moderator effects of study characteristics on high heterogeneity outcomes.
| VA improvement rate | CRT outcome, the end of follow up | |||||
|---|---|---|---|---|---|---|
| n | RR (95% CI) | p value | n | Slope (95% CI) | p value | |
| Study type (retrospective is ref.) | NA | NA | NA | 7 | 8.828 (-46.220 to 63.877) | 0.7533 |
| Quality score | 5 | 1.421 (0.683 to 2.958) | 0.3478 | 6 | -18.431 (-69.977 to 33.114) | 0.4834 |
| Mean age | 5 | 1.060 (0.977 to 1.150) | 0.1591 | 6 | 1.511 (-4.805 to 7.827) | 0.6392 |
| Study duration | 5 | 1.003 (0.970 to 1.038) | 0.8506 | 7 | 0.673 (-2.243 to 3.588) | 0.6510 |
a: the randomized controlled trial did not provide data on VA improvement rate; hence, meta-regression analysis of study type was not applicable.
Fig 3Trial Sequential Analysis (TSA) of the ERM recurrence rate outcome in this meta-analysis.
TSA is a methodology that includes a sample size calculation for a meta-analysis with the threshold of statistical significance. The detailed settings of this TSA were shown as follows: Significance level = 0.05; Power = 0.80; incidence of control = 2.3; relative risk reduction = 30%; I2 = 0%. Finally, the number of required samples is 1263 but this meta-analysis collected only 674 samples.